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Abstract
Background: Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), a cell
adhesion molecule expressed in a variety of cell types is a putative tumor suppressor gene.
Alternative splicing of CEACAM1 generates 11 different splice variants, which include 1–4
ectodomains with either short or long cytoplasmic domain generated by the exclusion
(CEACAM1-S) or inclusion (CEACAM1-L) of exon 7. Studies in rodents indicate that optimal ratios
of CEACAM1 splice variants are required to inhibit colonic tumor cell growth.
Results:  We show that CEACAM1 is expressed in a tissue specific manner with significant
differences in the ratios of its short (CEACAM1-S) and long (CEACAM1-L) cytoplasmic domain
splice variants. Importantly, we find dramatic differences between the ratios of S:L isoforms in
normal breast tissues versus breast cancer specimens, suggesting that altered splicing of CEACAM1
may play an important role in tumorogenesis. Furthermore, we have identified two regulatory cis-
acting elements required for the alternative splicing of CEACAM1. Replacement of these regulatory
elements by human β-globin exon sequences resulted in exon 7-skipped mRNA as the predominant
product. Interestingly, while insertion of exon 7 in a β-globin reporter gene resulted in its skipping,
exon 7 along with the flanking intron sequences recapitulated the alternative splicing of CEACAM1.
Conclusion: Our results indicate that a network of regulatory elements control the alternative
splicing of CEACAM1. These findings may have important implications in therapeutic modalities of
CEACAM1 linked human diseases.
Background
Alternative splicing is a process by which a single pre-
mRNA can generate multiple mRNA isoforms by differen-
tial joining of 5' and 3' splice sites (ss) [1,2]. Mapping of
the human genome suggests that more than 70% of genes
encode for transcripts that undergo alternative splicing [3-
5], and most alternative splicing events affect coding
capacity of genes [6,7]. Given the importance of mRNA
splicing in gene expression, it is not surprising that ~50%
of human genetic diseases may be caused by mutations of
the splice junctions or auxiliary regulatory sequences
[8,9]. However, sequencing of many cancer specific alter-
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natively spliced genes has indicated that genomic muta-
tions are not the only cause of aberrant splicing. In fact,
deregulated expression of splicing factors has been shown
to affect alternative splicing, which is often accompanied
by a shift in the ratio of alternatively spliced mRNA iso-
forms [10-15]. Accordingly, molecular strategies that
modulate alternative splicing have been the focus of atten-
tion over last several years [16-20].
CEACAM1 (carcinoembryonic antigen-related cell adhe-
sion molecule 1), also known as biliary glycoprotein [21]
or CD66a [22], is a transmembrane protein of the immu-
noglobulin superfamily [23]. It consists of N-terminal
ectodomain, either two or four extracellular Ig-like
domains, a conserved transmembrane domain, and either
a short (12–14 amino acids, CEACAM1-S) or long cyto-
plasmic domain (72–74 amino acids, CEACAM1-L) gen-
erated due to the alternative splicing of CEACAM1 pre-
mRNA. The inclusion of exon 7 in CEACAM1-L mRNA
shifts the open reading frame resulting in the use of a dis-
tant stop codon and expression of a long cytoplasmic
domain (72–74 amino acids). On the other hand, exclu-
sion of exon 7 produces a proximal stop codon thereby
generating a shorter mRNA that translates into a short
cytoplasmic domain (12–14 amino acids) [24,25] (Fig.
1). The long cytoplasmic domain encodes two ITIMs
(immunoreceptor tyrosine-based inhibitory motif) that
bind SHP-1 when phosphorylated and convey inhibitory
activities to CEACAM1-L [26]. The short cytoplasmic
domain has been shown to bind actin, tropomyosin, cal-
modulin, and annexin II [27,28] and is involved in lumen
formation [29].
CEACAM1 is expressed in a polarized luminal orientation
in the liver, colon and breast. It is downregulated in vari-
ous types of tumors such as colorectal carcinomas,
hepatomas, breast carcinomas, and prostate carcinomas
[30-33], suggesting a tumor suppressive role for
CEACAM1. Indeed, CEACAM1-L has been shown to pos-
sess tumor growth inhibitory activity when its gene is
transfected and expressed in prostate [34], bladder [35] or
breast cancer cells [36]. In addition, CEACAM1-L
decreases cell growth in response to insulin [37,38]. How-
ever, tumor suppressive role of CEACAM1-L has been
questioned by other findings. For example, the expression
of CEACAM1-L is upregulated in primary lung carcinomas
when compared with adjacent normal lung tissue [39].
Similarly, CEACAM1-L is expressed abundantly in several
human colon and thyroid carcinoma cell lines (this study
and see ref [25,40]). Importantly, in contrast to previously
held notion that the long cytoplasmic domain isoform of
CEACAM1 possesses tumor suppressive properties, we
recently showed that forced expression of CEACAM1-S
revert the malignant mammary epithelial cell line MCF7,
which expresses low levels of CEACAM1-L, to a normal
acinar morphology [29]. Together, these studies raise the
possibility that an optimal ratio of CEACAM1 S:L splice
variants may be important for maintaining normal cell
function. This is consistent with a study in rodents where
optimal ratios of CEACAM1 cytoplasmic domain splice
variants have been found to be essential for inhibiting
colonic tumor cell growth [41].
In this report, we set out to answer three important ques-
tions: 1) Do CEACAM1 transcripts undergo alternative
splicing in a tissue specific manner? 2) Is splicing of
CEACAM1 altered in breast cancer? and 3) What are the
cis-acting element(s) in exon 7 that regulate CEACAM1
alternative splicing in two different cytoplasmic domain
isoforms? Here we show that the ratios of CEACAM1
splice variants vary significantly among a variety of nor-
mal human tissues and cell lines derived from human
tumors. We further demonstrate that compared to normal
tissues, the ratios of CEACAM1 short to long cytoplasmic
domain splice variants vary significantly in breast cancer
specimens. Finally, we report the identification of two reg-
Schematic representation of human CEACAM1 gene and its alternative splicing into long and short cytoplasmic domain isoforms Figure 1
Schematic representation of human CEACAM1 gene and its alternative splicing into long and short cytoplas-
mic domain isoforms. Open boxes or lines represent exons and introns, respectively. Shaded portions of exons denote the 
leader sequence. The broken lines represent inclusion or exclusion of exon 7 thereby generating CEACAM1-L or CEACAM1-
S splice variants, respectively. Numbering of the exons is indicated below each exon. N, A1, B1 and A2 refer to the Ig domains 
[54]. UTR, untranslated region; ATG, the start codon; TM, transmembrane domain; CP, cytoplasmic domain; TGA and TAA, 
the stop codons for short and long cytoplasmic domain isoform, respectively.Molecular Cancer 2008, 7:46 http://www.molecular-cancer.com/content/7/1/46
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ulatory  cis-acting elements that control the alternative
splicing of CEACAM1.
Results
CEACAM1 long and short cytoplasmic domain splice 
variants are expressed differentially in normal human 
tissues
Alternative splicing of CEACAM1 generates two cytoplas-
mic domain splice variants that differ by the inclusion or
exclusion of exon 7 (Fig. 1). As a first step towards under-
standing the relationship between altered splicing of
CEACAM1 transcripts and neoplasia, we decided to exam-
ine the expression of CEACAM1 long and short cytoplas-
mic domain splice variants in a variety of human tissues.
Total RNAs from normal human tissues (brain, colon,
heart, kidney, liver, lung and prostate) were subjected to
RT-PCR with primers that were designed to specifically co-
amplify CEACAM1-L (408-bp) and CEACAM1-S (355-
bp) mRNA splice variants.
Fig. 2A demonstrates that colon, liver, lung and prostate
co-expressed CEACAM1-L and CEACAM1-S splice vari-
ants. While liver and prostate expressed higher levels of
CEACAM1-S splice variant, colon and lung expressed
more of the CEACAM1-L splice variant (Fig. 2A, compare
lanes 2, 5, 6 and 7). In contrast, brain, heart and kidney
almost exclusively expressed the CEACAM1-L splice vari-
ant (Fig. 2A, cf. lanes 1, 3 and 4). Even more striking are
the differences between the ratios of CEACAM1-S and
CEACAM1-L splice variants. For example, although colon,
liver, lung and prostate expressed both cytoplasmic
domain isoforms of CEACAM1, the S:L ratio in liver is sig-
nificantly higher than other tissues. Quantitation of the
data shown in Fig. 2B indicate that the ratio of S:L splice
variants in liver is 2, 5 and 8-fold higher than in prostate,
colon and lung, respectively.
Splicing of CEACAM1 exon 7 is altered in cancer cell lines
To determine whether altered splicing of CEACAM1 is
linked to tumorigenesis, we examined the splicing profile
of CEACAM1 transcripts in a variety of human cancer cell
CEACAM1 is differentially expressed in normal human tissues Figure 2
CEACAM1 is differentially expressed in normal human tissues. (A) Schematic diagram of RT-PCR strategy for the 
identification of CEACAM1 long and short cytoplasmic domain splice variants. Binding sites for the forward and reverse prim-
ers and the expected size of amplified fragments are shown. The PCR amplified products were separated by electrophoresis on 
a 2.5% agarose gel. M, refers to 100 bp DNA ladder (NEB). (B) Histogram shows CEACAM1-S/CEACAM1-L (S:L) ratio quanti-
fied with NIH ImageJ program.Molecular Cancer 2008, 7:46 http://www.molecular-cancer.com/content/7/1/46
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lines derived from brain, breast, colon and prostate. The
rationale for choosing these cell lines was based on the
fact that CEACAM1 has been extensively studied in colon
[42,43], prostate [34,44] and breast carcinomas [45].
Therefore, cell lines derived from these tissues should
serve as model system for assessing whether altered
CEACAM1 splicing is associated with cancer. Since very
little is known about the role of CEACAM1 in brain can-
cer, we also examined the expression of CEACAM1 in
three human malignant glioma cell lines, U87MG, U251T
and T98G. Glioma is a rapidly fatal cancer in which the
search for oncogenes and tumor suppressor genes is
important.
The results of the RT-PCR assay shown in Fig. 3A demon-
strate marked differences in the expression of CEACAM1
long and short cytoplasmic domain splice variants.
Human malignant glioma cell lines T98G and U87MG
mainly expressed the CEACAM1-L splice variant.
Although U251T cells expressed relatively lower levels of
CEACAM1-L, the S:L ratio in these cells (0.24) is signifi-
cantly higher compared to T98G (0.06) and U87MG
(0.05) cells (Fig. 3A cf. lanes 1–3 and see Fig. 3B). Colon
cancer cell lines, with the exception of HT29 and S1,
expressed for the most part short cytoplasmic domain
splice variant (Fig. 3A cf. lanes 8–12). The results with
breast and prostate cancer cell lines were somewhat
mixed. While breast cancer cell lines MDA-MB468 and
ZR75 expressed both splice variants, BT474 cells
expressed only the short splice variant (Fig. 3A cf. lanes 4–
7). The observation that MCF7 cells barely expressed
CEACAM1 is consistent with our earlier study [29].
Among the prostate cancer cell lines examined, PC3 and
DU-145 expressed both the short and long cytoplasmic
domain splice variants of CEACAM1: DU-145 cells
expressed more of the short splice variant, PC3 cells
largely expressed the long splice variant, and LNCaP cells
expressed only the short splice variant (Fig. 3A cf. lanes
13–15).
The expression profile of CEACAM1 in human cancer cell lines Figure 3
The expression profile of CEACAM1 in human cancer cell lines. (A) Total RNAs from the indicated cell lines were 
isolated and subjected to RT-PCR as described in Figure 2. The position of CEACAM1 long and short cytoplasmic domain 
splice variants is indicated on right. (B) Histogram depicting CEACAM1-S/CEACAM1-L (S:L) ratio in a logarithmic bar graph 
quantified with NIH ImageJ program. Data represent the mean ± SD of at least three independent experiments.Molecular Cancer 2008, 7:46 http://www.molecular-cancer.com/content/7/1/46
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A comparative analysis of S:L ratios between normal
human tissue and corresponding cancer cell line revealed
further insights. For example, normal colon co-expressed
both splice variants with S:L ratio of 0.67 (Fig. 2B). In con-
trast, colon cancer cell lines expressed elevated levels of
short splice variant with S:L ratios ranging between ~1.6–
21 (Fig. 3). The observed S:L splice variant ratio in PC3
(0.2) and DU-145 (2.3) cells was different compared to
normal prostate (1.7). Since LNCaP cells expressed only
the short splice variant, a direct comparison of the S:L
ratio between normal prostate and this cell line was not
possible. Unlike normal brain tissue that exhibited only
CEACAM1-L splice variant, malignant glioma cell lines
expressed both splice variants with significant differences
between S:L ratios (compare lane 1 in Fig. 2A with lanes
1–3 in Fig. 3A). These data indicate that S:L splice variant
ratio in U251T cells is 3.6 and 4.1-fold higher than T98G
and U87MG cells, respectively (Fig. 3B).
Altered splicing of CEACAM1 exon 7 and breast cancer
The results presented in the previous section suggest that
CEACAM1 is differentially expressed in various human
tissues and apparently alteration in the splicing pattern of
CEACAM1 is linked to tumorigenesis. To extend this study
further and to ascertain that altered splicing of CEACAM1
mRNA is linked to tumorigenesis, we isolated total RNAs
from a number of breast cancer tissues that were depos-
ited in the City of Hope tissue bank. These tissues were
surgically removed from patients who were between the
ages of 31–64 and had not undergone chemotherapy or
radiation treatment prior to surgery.
As shown in Fig. 4, CEACAM1 mRNA splice variants in
which exon 7 was excluded accounted for most of the
spliced transcripts in normal tissues (see lanes N1 and
N2). Quantitation of these data demonstrate that the
ratios of S:L cytoplasmic domain splice variants range
between ~15–17. In contrast, breast cancer specimens dis-
played expression of both short and the long cytoplasmic
domain splice variants of CEACAM1 with a marked
decrease in the ratio of S:L. Unlike normal tissues, the S:L
splice variant ratios in breast cancer specimens varied
from 1.0 to 7.8 (Fig. 4B). The combined results from nor-
mal human tissues, cancer cell lines and breast cancer
specimens suggest that alteration of CEACAM1 splicing
could be a common feature of breast cancer and an opti-
mal ratio between the short and the long cytoplasmic
domain splice variants might be required for normal tis-
sue function.
Identification of cis-acting elements that regulate the 
alternative splicing of exon 7
It is now widely accepted that regulation of alternative
splicing involves multiple cis-acting regulatory elements
and  trans-acting splicing regulators. An established
approach to identify such regulatory elements is to design
transfectable minigenes that could faithfully reproduce a
given splicing pattern in a cell line. To test whether a
CEACAM1 minigene could recapitulate exon 7 alternative
splicing, we PCR amplified a CEACAM1 cassette compris-
ing exons 6, 7 and 8, along with the entire intervening
intronic sequences from human genomic DNA. The PCR
amplified cassette was cloned downstream of a CMV pro-
moter in a mammalian expression vector yielding a mini-
gene construct (hereafter referred to as CAM 6-7-8, see Fig.
5A).
The breast cancer cell lines MDA-MB468 and ZR75 in
which CEACAM1 pre-mRNA undergoes alternative splic-
ing giving rise to both short and long cytoplasmic domain
splice variants (see Fig. 3) were transfected transiently
with CAM 6-7-8. After 24 h, total RNAs were extracted and
the relative abundances of CEACAM1-S and L splice vari-
ant mRNAs were estimated by RT-PCR with primers that
were designed to amplify specifically the transcripts
derived from minigene. We found that CAM 6-7-8 mini-
gene mimics the splicing profile of endogenous
CEACAM1 transcripts in both cell lines, albeit with some
differences in the ratios of short and long splice variants
(compare lane 4 in Fig. 5B and 5C with lanes 5 and 7 in
Fig. 3A). To excluded possibility that the observed splicing
patterns could be CMV promoter-dependent, we sub-
CEACAM1 pre-mRNA splicing is altered in breast cancer Figure 4
CEACAM1 pre-mRNA splicing is altered in breast 
cancer. (A) CEACAM1 splicing pattern in ten breast cancer 
specimens (1–10) and two normal-appearing (N1 and N2) 
breast tissues is shown. See Figure 2 and experimental sec-
tion for details. (B) Histogram representing the quantification 
of CEACAM1S/L ratio as determined in Figure 2. *P < 0.007 
versus normal.Molecular Cancer 2008, 7:46 http://www.molecular-cancer.com/content/7/1/46
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cloned CAM 6-7-8 minigene downstream of β-actin pro-
moter. Transient transfection followed by RT-PCR assay
indicated that although β-actin promoter exhibited lower
levels of CEACAM1 transcripts, the splicing profile and
the ratios of S:L splice variants were similar to the endog-
enous transcripts (data not shown). These results demon-
strate that the CAM 6-7-8 minigene can be used to identify
cis-acting sequences that are responsible for controlling
the splicing of exon 7.
Identification of CEACAM1 regulatory sequences required for the splicing of exon 7 Figure 5
Identification of CEACAM1 regulatory sequences required for the splicing of exon 7. (A) Schematic representation 
of CEACAM1 minigene or chimeras cloned into pcDNA 3.1/Myc-His(-) C. Open or shaded boxes are exons and lines repre-
sent introns. The name of each minigene is indicated on right. The size of middle exon in all minigenes is identical to exon 7 of 
CEACAM1. In CAM 6-βg-8 the entire middle exon is replaced by 53 bp of •-globing exon 2. In minigenes CAM 6-E7.1•g-8 and 
CAM 6-E7.2•g-8, the first and the last 20 bp (E7.1 and E7.2 regions) of CEACAM1 exon 7 are replaced by •-globin exon 2 
sequences. The forward (T7) and reverse priming sites (BGH) are indicated. (B and C) RT-PCR analysis of RNA derived from 
MDA-MB468 and ZR75 cells transiently transfected with indicated minigenes or empty vector. -RT represents omission of 
reverse transcriptase during cDNA synthesis. The data shown is representative of three independent experiments. Bar dia-
grams represent the mean ± SD of at least three independent experiments. *P < 0.001 and **P < 0.01 versus CAM 6-7-8.Molecular Cancer 2008, 7:46 http://www.molecular-cancer.com/content/7/1/46
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As a first step to identify the regulatory elements that con-
trol exon 7 splicing, we constructed a series of chimeric
minigenes and examined the splicing pattern of the tran-
scripts derived from these minigenes in MDA-MB468 and
ZR75 breast cancer cell lines. We replaced exon 7 (53 nt)
with the first 53 nt of human β-globin exon 2 to yield
pCAM 6-βg-8 (Fig. 5A). Splicing profile of CAM 6-βg-8
transcripts in MDA-MB468 and ZR75 cell lines gave rise to
spliced mRNAs lacking middle exon, suggesting that exon
7 contains regulatory element(s) that are required for its
splicing (see lane 5, Fig. 5B and 5C).
To dissect the exon 7 sequences that contribute to its splic-
ing, we constructed two minigenes in which first (E7.1
region) or the last 20 nucleotides (E7.2 region) were
replaced by sequences of human β-globin exon 2 to yield
CAM 6-E7.1βg-8 and CAM 6-E7.2βg-8, respectively (Fig.
5A). The transcripts encoded by CAM 6-E7.1βg-8 mini-
gene resulted in skipping of exon 7 in both cell lines (see
lane 6 in Fig. 5B and 5C). In contrast, CAM 6-E7.2βg-8
pre-mRNA gave rise to small but reproducible inclusion of
middle exon in MDA-MB468 cell line, but only exon
skipped mRNA in ZR75 (see lane 7 in Fig. 5B and 5C).
These data imply that exonic sequences in the immediate
vicinity of the 5' and 3' ss play an important role in the
splicing of exon 7.
Regulatory elements in exon 7 and flanking intronic 
sequences are important for controlling CEACAM1 
alternative splicing
To further investigate the mechanism of exon 7 splicing
regulation we tested the splicing of CEACAM1 exon 7 in a
heterologous context in complete absence of flanking
exons, but either lacking or containing majority of the
flanking intron sequences. To this end, we cloned
CEACAM1 exon 7 without (βg-ΔiE7-βg) or with (βg-E7-
βg) the flanking intron sequences between two constitu-
tive β-globin exons of the pDUP5-1 (Fig. 6A). Minigene
βg-ΔiE7-βg consists entirely of β-globin-derived
sequences, with the exception of 53 nucleotides of exon 7
that replaced the central exon. On the other hand, mini-
gene βg-E7-βg contains entire exon 7 and the flanking
intron sequences with the exception of 5' and 3' ss of exon
6 and 8, respectively. These reporters were transiently
expressed in MDA-MB468 and ZR75 cells and after 24 h
total RNA was isolated followed by RT-PCR with vector
specific primers. Consistent with a previously published
report [46], DUP5-1 generated transcripts gave rise to con-
stitutively spliced mRNA in both cell lines as evident by
the formation of ~600 bp product (see lane 4 in Fig. 6B
and 6C). The splicing of βg-ΔiE7-βg transcripts also pro-
duced a single mRNA species with a molecular size of
~500 bp. Since the expected size of exon 7 included
mRNAs is ~600 bp, the observed ~500 bp product is indic-
ative of exon 7 skipping (Fig. 6B and 6C, cf. lane 5). To
verify that the splicing of βg-ΔiE7-βg pre-mRNA resulted
in exon 7 skipped mRNA, ~500 bp band was excised and
subjected to DNA sequencing. Examination of sequencing
results (data not shown) confirmed that βg-ΔiE7-βg pre-
mRNA gave rise to exon 7-skipped mRNA in both cell
lines. Interestingly, in both cell lines the splicing of βg-E7-
βg transcripts gave rise to mRNAs with or without exon 7,
suggesting that the flanking intron sequences play a vital
role in the regulation of CEACAM 1 alternative splicing
(see lane 6, Fig. 6B and 6C). To confirm that these mRNAs
were not generated due to cryptic splice site activation, the
identity of each mRNA was confirmed by DNA sequenc-
ing (data not shown). We conclude that sequences resid-
ing in exon 7 as well as flanking introns are required for
the regulation of CEACAM1 alternative splicing.
Discussion
CEACAM1 plays an important role in many aspects of epi-
thelial cell function. Although the role of CEACAM1 as a
tumor suppressor gene in colon and prostate has been
investigated in great detail, its exact role in breast cancer is
less well defined. For example, while downregulation of
CEACAM1 gene has been suggested to contribute to the
development of >90% of colon cancers [43], the lack of
CEACAM1 expression account for ~30% of breast cancer
[45]. In fact, we have recently shown that forced expres-
sion of CEACAM1-S in the mammary epithelial cell line
MCF7, which only expresses a small amount of the long
splice variant, reverts the growth of these cells to a normal
acinar morphology in 3D culture [29]. Thus, it appears
that restoration of expression of the short splice variant is
important for the normal function of breast epithelial
cells. This idea is supported by the analysis of short and
long splice variants in normal breast tissue where the ratio
of S:L was ~15–16. In the case of breast cancers, the ratio
of S:L was between 1.0 to 7.8, but never reached the level
found in normal breast (Fig. 4). Thus, the increased
expression of the long splice variant may be a prognostic
indicator for breast cancer. However, it should be noted
that this study was performed at the mRNA level and
requires further examination of the protein level, an anal-
ysis that requires the use of isoform-specific antibodies.
The importance of the expression of the short cytoplasmic
domain splice variant in normal breast requires some
thought, since it is the long splice variant that contains
two ITIMs which are expected to convey inhibitory func-
tions. Indeed, this is the case for T-cells, where the long
isoform is exclusively expressed and its presence inhibits
T-cell proliferation and release of IL-2 [47-49]. The
absence of inhibitory motifs or association with inhibi-
tory molecules would seem to predict that the short splice
variant would not act as a tumor suppressor, but instead,
it appears that the opposite is true. For example,
CEACAM1 is a negative prognosticator in melanoma [50],Molecular Cancer 2008, 7:46 http://www.molecular-cancer.com/content/7/1/46
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Regulatory elements in Exon 7 and flanking intronic sequences are important for controlling CEACAM1 alternative splicing Figure 6
Regulatory elements in Exon 7 and flanking intronic sequences are important for controlling CEACAM1 alter-
native splicing. (A) The DUP5-1 minigene shown here contains three exons and two introns derived from human β-globin 
gene and is essentially identical to previously described version [46] except that vector backbone is pcDNA 3.1/Myc-His(-) C. 
The middle exon is a chimera of β-globin exon 1 and 2. The name of each minigene and exon and intron sizes are indicated. 
Minigene βg-ΔiE7-βg is a derivative of DUP5-1 in which the middle exon 2 is replaced by exon 7 of CEACAM1. Minigene βg-
E7-βg was created by digesting pDUP5-1 with ApaI and BglII and inserting PCR amplified CEACAM1 fragment that contains 
exon 7 and the flanking introns 6 and 7 (thick line) except first 150 bp in intron 6 and last 94 bp in intron 7. (B and C) RT-PCR 
analysis of MDA-MB468 and ZR75 cells transfected with the indicated minigenes or empty vector. -RT represents omission of 
reverse transcriptase during cDNA synthesis. The data shown is representative of three independent experiments. Bar dia-
grams represent the mean ± SD of at least three independent experiments. *P < 0.001 versus DUP5-1.Molecular Cancer 2008, 7:46 http://www.molecular-cancer.com/content/7/1/46
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and we have found that only the long cytoplasmic
domain splice variant is expressed in this cancer (unpub-
lished results). Thus, CEACAM1 splice variants may act in
a tissue specific manner where the context of cell signaling
may be very different from one cell or tissue to another.
Furthermore, the association of the short splice variant
with the cytoskeleton may be a key factor, since abnormal-
ities in the cytoskeleton are a common defect in cancers
[51].
In consideration of a role for different ratios of the short
and long cytoplasmic domain splice variants, a recent
study has shown in hepatocytes and polarized kidney cells
that the long isoforms are shuttled to cell-cell boundaries
and the short isoforms to the luminal surface [52]. Thus,
it appears that the two types of isoforms have distinct
roles in tissue organization. Indeed, we find that forced
expression of the short isoform in MCF7 cells grown in 3D
culture leads to expression at the luminal surface [29]. It
can be speculated that alteration of physiologically impor-
tant ratios of S:L isoforms would disrupt epithelial cell
polarization, which is a hallmark of epithelial cell cancers
[51,53].
Alternative splicing is a widespread phenomenon that
expands the size of human proteome and generates pro-
teins with functionally diverse properties. A number of
human genes employ alternative splicing to express phys-
iologically important levels of mRNA isoforms that play a
crucial role in cell homeostasis. In fact, several recent stud-
ies have indicated that a slight change in the delicate bal-
ance of mRNA splice variants is associated with human
genetic diseases and various forms of cancer (reviewed in
Ref [8,16]). However, the underlying mechanisms regulat-
ing the alternative splicing of genes associated with
human diseases are not fully understood.
Previous studies aimed at understanding the function of
human CEACAM1 for most part examined the expression
of CEACAM1-L mRNA or protein without taking into
account the potential contribution of short cytoplasmic
domain splice variant or effect of the ratios between the
long and short cytoplasmic domain splice variants. Here
in this study, we find that the pattern of CEACAM1 splic-
ing and the ratios of S:L splice variants vary in a variety of
normal human tissues. Importantly, compared to normal
tissues, alterations in the ratios of CEACAM1 cytoplasmic
domain isoforms are observed in cancer cell lines and
breast cancer specimens (Fig. 2, 3, 4). In an effort to iden-
tify cis-acting regulatory elements that control the alterna-
tive splicing of CEACAM1, we constructed a series of
minigenes and examined their splicing by transiently
transfecting two breast cancer cell lines, MDA-MB468 and
ZR75. We observed that substitution of β-globin exon 2
sequences for exon 7 (without changing the size of the
exon) resulted in the skipping of middle exon (Fig. 5B and
5C, cf lane 5). Likewise, replacement of the first or the last
20 residues in exon 7 by the corresponding β-globin exon
2 sequences failed to prevent exon skipping (Fig. 5B and
5C, see lanes 6–7). These data suggest the presence of reg-
ulatory cis-acting elements that promote exon 7 splicing.
However, skipping of exon 7 in the context of a β-globin
reporter construct indicate that additional regulatory ele-
ments within the flanking introns contribute to the splic-
ing of exon 7 (see lane 5 in Fig. 6B and 6C). Support to
this interpretation comes from the observation that β-
globin reporter (βg-E7-βg) comprising of exon 7 and
flanking intron sequences recapitulate the alternative
splicing of CEACAM1 in both breast cancer cell lines (Fig.
6B and 6C, lane 6). Together these data strongly suggest
that a complex regulatory network involving interactions
between sequence elements in exon 7 and the flanking
introns may be required for the splicing of exon 7. Clearly,
a detailed experimental analysis will be required to map
the regulatory elements necessary for the splicing of
CEACAM1.
Conclusion
The present study was undertaken to better understand
the relationship between CEACAM1 expression and neo-
plasia. Our results show that CEACAM1 is expressed in a
tissue dependent manner with significant differences in
the ratios of its short (CEACAM1-S) and long (CEACAM1-
L) cytoplasmic domain splice variants. Our data in human
breast cancer show a higher ratio of S:L in normal versus
malignant tissues, raising the possibility that tumor sup-
pressive role of CEACAM1 may actually depend on which
isoform is dominant. In addition, we have identified two
cis-acting elements required for the regulation of
CEACAM1 splicing into long or the short cytoplasmic
domain isoforms. These sequences could serve as a target
to modulate CEACAM1 alternative splicing, which may
have important therapeutic implications.
Methods
Plasmid construction
All DNA constructs were generated by standard cloning
procedures and confirmed by sequencing. The minigene-
splicing cassette CAM 6-7-8 was constructed by amplify-
ing human genomic sequences from exon 6 to exon 8
with Pfu DNA polymerase (Stratagene) and primers
#40563 (5'-AAAAAAAAGCTAGCCTCGAGATAATGCTC-
TACCACAAGAAAATGG-3') and #41658 (5'-AACTGCA-
GAAGCTTCCTTGTTAGGTG-3'). The underline sequences
represent NheI and HindIII restriction enzyme sites. The
PCR amplified DNA was digested with NheI and HindIII
(New England Biolabs) and cloned into pcDNA 3.1/Myc-
His(-) C (Invitrogen). The CAM 6-βg-8 minigene was
engineered by two-step overlapping PCR approach using
CAM 6-7-8 minigene as template. In the first step, theMolecular Cancer 2008, 7:46 http://www.molecular-cancer.com/content/7/1/46
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upstream and the downstream portions of the minigene
were generated by using primers # 40563 and #45361 (5'-
AAAGAACCTCTGGGTCCAAGGGTAGACCACCAG-
CAGCCTAAATAAATATCAGAAACTGTG-3') and primers
#41658 and #45360 (5'-
TTGGACCCAGAGGTTCTTTGAGTCCTTTGGGGATCG-
TAAGTAAAGCCACTTACCC-3'), respectively. The first
step PCR products were used as template for the overlap-
ping PCR with primers #40563 and #41658. The ampli-
fied fragment was digested with NheI and HindIII, gel
purified, and ligated to pcDNA 3.1/Myc-His(-) C linear-
ized with appropriate restriction enzymes. The minigenes
CAM 6-E7.1βg-8 and CAM 6-E7.2βg-8 in which the first
and the last 20 nt of exon 7 were replaced by β-globin
sequences were essentially made following two-step over-
lapping PCR-based cloning using pCAM 6-7-8 as a tem-
plate. The following primer sets were used to generate
indicated constructs:
CAM 6-E7.1βg-8: #46888-ET7 (5'-GAAATTAATACGACT-
CACTATAGGG-3'); #48125 (5'-AAGGGTAGACCACCAG-
CAGCCTAAATAAATATCAGAAACTGTG-3'); #48124 (5'-
GCTGCTGGTGGTCTACCCTTTCACAGAGCACAAAC-
CCTCAG-3'); #46889-EBGH-R (5'-AACTAGAAG-
GCACAGTCGAGGC-3').
CAM 6-E7.2βg-8: #46888-ET7; #48127 (5'-
GATCCCCAAAGGACTCAAAGTTGTGCTCTGTGAGAT-
CACG-3'); #48126 (5'-CTTTGAGTCCTTTGGGGATCG-
TAAGTAAAGCCACTTACCCC-3'); #46889-EBGH-R. The
minigene DUP5-1 has been previously described [46]
except that the sequence from 549 to 1228 was PCR
amplified using primers #47240 (5'-AAACCGCTCGAG-
GCTAGCTCAGCTTGCTTACATTTGCTTCTG-3') and
#47241 (5'-AACTGCAGAAGCTTGGATCCACGT-
GCAGCTTGTCAC-3'), and NheI/HindIII digested frag-
ment cloned in pcDNA 3.1/Myc-His(-) C. The minigenes
βg-ΔiE7-βg and βg-E7-βg are derivatives of pDUP5-1. The
plasmid pβg-ΔiE7-βg was constructed by overlapping PCR
using pDUP5-1 as template and primers #47240; #48386
(5'-TCTGTGAGATCACGCTGGTCGCTTGCCCTAAGGGT-
GGGAAAATAGAC-3'); #47241 and #48387 (5'-GAC-
CAGCGTGATCTCACAGAGCACAAACCCTCAGTCTCCA
ACCACAGTTGGTATCAAGGTTACAAGA-3'). The NheI/
HindIII digested fragment was cloned in pcDNA 3.1/Myc-
His(-) C. Plasmid pβg-E7-βg was created by digesting
pDUP5-1 with ApaI and BglII and inserting CEACAM1
fragment from 151 to 1500 (1 represents the first nucle-
otide in intron 6), which was amplified by PCR using
pDUP5-1 as template and primers #43355 (5'-AGCT
GGGCCCGTTCTGTTTCCTCCAAGGC-3') and #43356
(5'-GGATAGATCTAGCTGAAGGAGGTGGC-3'). The
underline sequences in #43355 and #43356 represent rec-
ognition sequence for ApaI and BglII restriction enzymes.
Cell culture
The human breast (BT474, MCF7, MDA-MB468 and
ZR75) and prostate (PC3, LNCaP and DU-145) cancer cell
lines were obtained from American Type Culture Collec-
tion (Manassas, VA). The glioma cell lines U251T, T98G
and U87MG and colon cancer cell lines HT29, HCT116 (-
/+ p53), S1 and HCC2998 were kind gifts from Drs. John
Shively and Y. Yen (City of Hope). The breast cancer cell
lines, with the exception of MDA-MB468, are ER positive,
express HER2/neu, and were derived from metastatic sites.
The prostate cancer cell lines used in this study are meta-
static. While LNCaP is hormone sensitive, PC3 and DU-
145 lines are hormone-refractory. The human glioma cell
lines U251T is the tumorigenic strain of U251. The line
U87MG is derived from malignant gliomas and unlike
T98G it is considered to be tumorigeneic. The human
colon cancer cell lines HT29, HCT116 and HCC2998 are
tumorigenic. The S1 is a human colon cancer cell line
derived from the S1 clone of tumorigenic LS-180 colon
carcinoma cell line. These cell lines were culture in ATCC
recommended cultured conditions using following
growth mediums (RPMI 1640, MEM containing 2%
glutamine, DMEM with high glucose or McCoy's
medium) supplemented with 10% heat-inactivated fetal
bovine serum (Omega Scientific Inc., CA) at 37°C in
humidified air containing 5% CO2.
Transient transfection, RNA isolation and RT-PCR
A day prior to transfection, 5 × 105 MDA-MB468 or ZR75
cells were seeded on a 6 well plate. Next day, 2.5 μg plas-
mid was transfected with Lipofectamine 2000 (Invitro-
gen) following manufacturer's instructions. After 24
hours, cells were harvested and total RNA was isolated
using RNeasy total RNA isolation kit (Qiagen) and treated
with DNase I (Roche). Total RNA (3–5 μg) was subjected
to reverse transcription with oligo (dT)20  and MMLV
reverse transcriptase (Invitrogen) essentially according to
the manufacturer's instructions. Next, 1 μL of RT mixture
was PCR amplified using vector specific primers ET7 (5'-
GAAATTAATACGACTCACTATAGGG-3') and EBGH-R
(5'-AACTAGAAGGCACAGTCGAGGC-3'). The PCR
amplification conditions were as follows: 94°C for 5 min;
30 cycles at 94°C for 45 sec, 60°C for 1 min, and 72°C for
1 min; and a final extension at 72°C for 10 min. The PCR
amplified products were analyzed by electrophoresis on a
2.5% agarose gel, and quantified by ImageJ software ver-
sion 1.36b (National Institutes of Health).
Analysis of CEACAM1 splicing in normal human tissues, 
breast cancer specimens and cancer cell lines
To examine the expression of endogenous CEACAM1
long and short cytoplasmic domain mRNAs, we isolated
total RNA from breast cancer specimens and the non-dis-
eased breast tissues that were deposited in City of Hope
tissue bank. The breast tumors of all of the treated patientsMolecular Cancer 2008, 7:46 http://www.molecular-cancer.com/content/7/1/46
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were removed by complete surgical resection at City of
Hope and a written consent was received from patients or
family members. The institutional review board approved
the research protocol. The clinical history of breast cancer
specimens is detailed below. The specimen no. 1, 3, 5, 6
and 9 are invasive ductal adenocarcinoma; 2 and 8 ductal
carcinoma; and remainder designated as breast carci-
noma. All of the ten patients showed lymph node metas-
tases of breast cancer and tumors were moderate-to-
poorly differentiated. Typically ~30 mg frozen tissue sam-
ple or 5 × 105 pelleted cells were homogenized followed
by the isolation of total RNA using RNeasy kit essentially
as described in the protocol (Qiagen). Total RNA from
normal human tissues (brain, colon, heart, kidney, liver,
lung and prostate) were obtained from Ambion (Austin,
TX) and directly used for reverse-transcription-PCR as
described above, except that oligonucleotide # 43309 (5'-
GGTTGCTCTGATAGCAGTAG-3') and # 43310 (5'-
AGCCTGGAGATGCCTATTAG-3') were used as forward
and reverse primers, respectively. Since the binding sites
for forward and reverse primers are located in exon 6 and
the 3' UTR, respectively, which are interrupted by three
introns, the presence of contaminating genomic DNA
amplification would be easily detected. In addition, we
followed previously reported PCR amplification condi-
tions that represent linear amplification of both mRNA
species in a single reaction [39].
Statistical Analysis
The results obtained in this study represent mean ± SD
from at least three independent experiments. The statisti-
cal significance of data groups was performed with Stu-
dent's t-test.
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